KEY TAKEAWAYS: 70% of Sponsors miss their milestones by an average of eight months, suggesting the clinical trial recruitment ...
Eisai and Biogen scored an approval for once-monthly IV maintenance dosing of their Alzheimer’s drug Leqembi, as part of what ...
A London-based biotech has emerged from stealth with a personalized T cell therapy platform that it says could create ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback